

Syngene announces senior-level appointments

Strengthens leadership in USA

- Alex Del Priore appointed as Senior Vice President, Manufacturing Services
- Alan Collis appointed as Vice President, Integrated Drug Discovery Services

Bengaluru, India, 4 July 2021: Syngene International, an integrated research, development, and manufacturing services company, has appointed two senior leaders, Alex Del Priore and Dr. Alan Collis, with effect from 26th July 2021. Alex Del Priore has been appointed as the Senior Vice President, Manufacturing Services. Alan Collis joins as the Vice President, Integrated Drug Discovery services. They will both be based in the United States of America (USA), which is one of the key markets for the Company.

Alex Del Priore is a member of the Executive Committee and will provide strategic direction for growth of the manufacturing services business leveraging the Company's discovery and development strengths for effective end-to-end offering. He is responsible for the growth of API outcomes from Syngene's new facility in Mangalore and will develop a sustainable client base for the business in collaboration with the commercial and business development teams. Alex will also be responsible for the growth of the large molecule operations and will oversee Syngene's Biologics operations unit to continue building it as a diversified manufacturing business. He reports to Dr. Mahesh Bhargat, Chief Operating Officer.

Alan Collis will be joining as the leader of the SynVent team. SynVent is Syngene's platform for integrated discovery and early development, delivering upon strategies built in collaboration with and on behalf of clients to advance novel molecules into clinical trials. He will be responsible for the formulation and implementation of Syngene's overall Integrated Drug Discovery (IDD) scientific strategy and will oversee the end-to-end execution of client programs. He reports to Kenneth Barr, Sr. Vice President, Discovery Services.

Commenting on the appointments, **Jonathan Hunt, Managing Director and Chief Executive Officer, Syngene International Ltd.,** said, "As we continue our rapid growth in the global CRO/CDMO marketplace, these hires align with Syngene's focus on providing end-to-end solutions for discovery, development, and manufacturing across a range of therapeutic areas and modalities. We look forward to having Alex and Alan on board, which will help strengthen our position as a partner in innovation for our clients and to steer Syngene towards new growth milestones."

Alex Del Priore said, "I am delighted to take on my new role at Syngene and contribute towards pushing the boundaries of science in manufacturing and advanced therapies in biologics. As part of an integrated scientific solutions provider for multiple industries, I look forward to the exciting journey."

Alex Del Priore has an impeccable track record of over two decades in the development, commercialization, and life-cycle management of products in various lifescience industries. He has also served as general manager with global P&L responsibility. In addition, he has been instrumental in M&A, strategy development, & new product introduction.

Alan Collis said, "As a 'hand on' cross-functional scientist, I am thrilled to have this opportunity to join and help grow Syngene. I aim to swiftly progress the great scientific insights of our partners into clinical evaluation. The path requires a thoroughly connected and integrated strategy sitting squarely across our multiple proven capabilities in research, development, and manufacturing."

Alan Collis is a drug discovery and development scientist specializing in discovery, preclinical, and early clinical project leadership. Alan has served the European and US markets in various leadership roles, with responsibilities including medicinal chemistry, DMPK, safety assessment, CMC, and phase I studies. He has led 33 novel small molecules into preclinical evaluation by partnering with a diverse set of teams (internal and external) that initiated multiple clinical studies of new science.

About Syngene

Syngene International Ltd. (BSE: 539268, NSE: SYNGENE, ISIN: INE398R01022) is an integrated research, development and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods and specialty chemical sectors. Syngene's more than 4700 scientists offer both skills and the capacity to deliver great science, robust data management and IP security and quality manufacturing at speed to improve time-to-market and lower the cost of innovation. With a combination of dedicated research facilities for Amgen, Baxter, Bristol-Myers Squibb and Herbalife, as well as 2 Mn sq. ft of specialist discovery, development and manufacturing facilities, Syngene works with biotech companies pursuing leading-edge science as well as multinationals, including GSK and Merck KGaA.

For more details, visit www.syngeneintl.com